Blood: U.S. scientists try a new treatment for leukemia

Introduction: Blood cancer, also known as blood cancer (Leukemia), is commonly known as leukemiaLeukemia is a kind of hematopoieticstem cellsmalignant cloning diseaseChina has included it as one of the top ten malignant tumors in the key prevention and treatmentWith the progress of leukemia treatment research, the efficacy is constantly improving, but how to cure leukemia is still a difficult problemResearchers from Boston University School of Medicine in the United States recently tried a new treatment for leukemia, giving new hope to the diseasemyogenic tumor is a form of leukemia caused by a pathological mutation in bone marrow stem cells that causes the body to produce too many red blood cells, white blood cells and plateletsMost patients die as a result of further development of the disease or bone marrow fibrosisThere is currently no specific treatment for bone marrow fibrosisBut researchers at Boston University recently tried a new treatment and found that suppressing a special protein can reduce the number of macronuclear cells, thereby increasing the survival rate of patients with bone marrow hyperplial tumorsstudy led by DrShinobu Matsuura of Boston University School of Medicine and published in BloodEntitled "Adhesion to fibronectin via alpha5 beta1 integrin supports s expansion of the megakaryocyte lineage in primaryy myelosisin order to improve the survival rate of patients with bone marrow hyperplasia tumors, the researchers inhibited a special protein (alphabeta1 integrator) in the experimental model to reduce the number of large bone marrow cells (mega-nuclear cells)meganuclearcell (Megakaryocyte), a cell in the bone marrow that differentiates from hematopoietic stem cells, is a mature cell in a normal bone marrow that produces platelets, formerly a granulocyte The cell is large, and the limbo of the mature macronuclear cell partially breaks off and forms platelets It has been observed that the increase in the number of macronuclear cells is an important reason for the impact of bone marrow hyperplial tumors on the human body Excessive accumulation of extracellular matrix (ECM) is a sign of primary bone marrow fibrosis (PMF) Since cells are able to adhere to the surrounding extracellular matrix through integrator receptors, Shinobu Matsuura et al explore the hypothesis that "abnormal extracellular matrix integrator receptor axis is the cause of the increase of bone marrow macronuclear cells in JAK2V617F and PMF." researchers found that Vav1-hJAK2V617F genetically modified mice (JAK2V617F) had high bone marrow protein binding protein (FN) levels associated with macronucleosis and fibrosis In addition, compared to the wild control group, the macronuclear cells of the JAK2V617F-plus mice increased the cell surface expression of the main receptor of FN in the macronucleocytes, alpha5 beta1 integrator alpha5, and enhanced adhesion to FN They effectively reduced the percentage of CD41-JAK2V617F-meganuclear-core cells in and out of the body by reducing the adhesion of the inhibitory antibodies of alpha5 This confirmed the findings in mice that the patient's JAK2V617F-meganuclear cells showed an increase in the expression of alpha5, and the neutralizing antibodies of alpha5 sub-cells decreased the adhesion with FN, and reduced the number of cyanocells in CD34 plus cells "So far, most drug development has focused on the JAK2V617F mutation, but this approach has not fundamentally changed the course of the disease," explains Dr Shinobu Matsuura, the first author of the article Our study has taken an entirely new approach to the disease, and if successful, it will provide a treatment that complements or even replaces existing treatments," , whose ultimate goal, according to researchers, is to find effective treatments for bone marrow fibrosis, a terminal disease that can be followed by many diseases and without special treatment They also say bone marrow hyperplout is a chronic and debilitating disease If safe and effective new treatments can be found, the quality of life of these patients will be greatly improved